786 Neonatal outcomes in pregnant women with diagnosis of COVID-19

dc.contributor.authorIzewski, Joanna
dc.contributor.authorBoudova, Sarah
dc.contributor.authorRouse, Caroline E.
dc.contributor.authorIbrahim, Sherrine A.
dc.contributor.authorShanks, Anthony L.
dc.contributor.authorReinhardt, Jeff C.
dc.contributor.authorScifres, Christina
dc.contributor.authorHaas, David M.
dc.contributor.authorPeipert, Jeffrey F.
dc.contributor.authorTuuli, Methodius G.
dc.contributor.departmentObstetrics and Gynecology, School of Medicine
dc.date.accessioned2024-09-23T12:25:16Z
dc.date.available2024-09-23T12:25:16Z
dc.date.issued2021
dc.description.abstractObjective It is unclear whether infection with COVID-19 during pregnancy increases the risk of adverse neonatal outcomes. We tested the hypothesis that a diagnosis of COVID-19 during pregnancy increases the risk of neonatal respiratory morbidity and other adverse neonatal outcomes. Study Design: Retrospective analysis of prospectively collected data from two labor and delivery units with universal COVID-19 testing policy between March 1 and May 31, 2020. Pregnant women with singleton pregnancies who delivered during the study period and underwent testing for COVID-19 at any point in their pregnancy were eligible. The primary outcome was a composite of neonatal respiratory morbidity defined as the occurrence of any one of the following: respiratory distress syndrome, transient tachypnea of the newborn, and need for respiratory support. The risk of neonatal morbidity with and without a COVID-19 diagnosis were compared using univariable and multivariable analyses. Stratified analysis compared the risks of adverse neonatal outcomes in symptomatic and asymptomatic patients with COVID-19 to those without COVID-19. Results: Of 515 subjects meeting inclusion criteria, 55 (10.7%) tested positive for COVID-19; 19 (34.6%) were asymptomatic and 36 (65.4%) were symptomatic. No neonate tested positive for COVID-19. Rates of the primary outcome, composite neonatal respiratory morbidity, were not significantly different in patients with and without COVID-19 (21.8% vs 19.6%, P=0.692). There was no significant difference in the risk of neonatal respiratory morbidity in a Cox regression model accounting for time from diagnosis to delivery, and adjusting for gestational age at delivery, mode of delivery, and maternal diabetes (adjusted hazard ratio: 0.62; 95% CI 0.35, 1.09). There were no significant differences in any of the secondary outcomes in patients with COVID-19 who were asymptomatic or symptomatic (Table). Conclusion: A diagnosis of COVID-19 during pregnancy does not appear to increase the risk of neonatal morbidity. These data may be useful in counseling women diagnosed with COVID-19 during pregnancy.
dc.eprint.versionFinal published version
dc.identifier.citationIzewski J, Boudova S, Rouse CE, et al. 786 Neonatal outcomes in pregnant women with diagnosis of COVID-19. Am J Obstet Gynecol. 2021;224(2):S489-S490. doi:10.1016/j.ajog.2020.12.809
dc.identifier.urihttps://hdl.handle.net/1805/43507
dc.language.isoen_US
dc.publisherElsevier
dc.relation.isversionof10.1016/j.ajog.2020.12.809
dc.relation.journalAmerican Journal of Obstetrics & Gynecology
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCOVID-19
dc.subjectPregnancy
dc.subjectNeonatal respiratory morbidity
dc.title786 Neonatal outcomes in pregnant women with diagnosis of COVID-19
dc.typeAbstract
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848499/
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Izewski2021Neonatal-PP.pdf
Size:
1.14 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: